Cargando…
IMMU-31. PNOC007: H3.3K27M SPECIFIC PEPTIDE VACCINE COMBINED WITH POLY-ICLC FOR THE TREATMENT OF NEWLY DIAGNOSED HLA-A2+ H3.3K27M DIFFUSE MIDLINE GLIOMAS (DMG)
OBJECTIVE: To assess safety and efficacy within a multi-center trial the H3.3K27M specific peptide vaccine with poly-ICLC in HLA-A02.01(+) patients diagnosed with H3.3K27M(+) DMGs. METHODS: After focal radiation therapy, participants 3–21 years of age were enrolled into two strata. Stratum A: newly...
Autores principales: | Mueller, Sabine, Taitt, Jared, Bonner, Erin, Lulla, Rishi, Goldman, Stewart, Banerjee, Anu, Chi, Susan, Whipple, Nicholas S, Crawford, John, Gauvain, Karen, Nazemi, Kellie, Watchmaker, Payal, Nejo, Takahide, Okada, Kaori, Butterfield, Lisa H, Nazarian, Javad, Villaneuva-Meyer, Javier, Molinaro, Annette M, Prados, Michael, Okada, Hideho |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715716/ http://dx.doi.org/10.1093/neuonc/noaa222.385 |
Ejemplares similares
-
IMMU-23. A NOVEL MASS CYTOMETRY-BASED MULTI-PARAMETER CHARACTERIZATION OF NEOANTIGEN-REACTIVE CD8+ T-CELLS IN PATIENTS PARTICIPATING IN PNOC007 H3.3K27M PEPTIDE VACCINE CLINICAL TRIAL
por: Taitt, Jared, et al.
Publicado: (2020) -
Novel and shared neoantigen for glioma T cell therapy derived from histone 3 variant H3.3 K27M mutation
por: Hou, Yafei, et al.
Publicado: (2015) -
Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy
por: Chheda, Zinal S., et al.
Publicado: (2018) -
The H3.3K27M oncohistone antagonizes reprogramming in Drosophila
por: Ahmad, Kami, et al.
Publicado: (2021) -
Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch et al
por: Chheda, Zinal S, et al.
Publicado: (2023)